Amgen Cholesterol Drug Wins U.S. Approval to Treat Some Patients

Amgen Inc. won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market.

The Food and Drug Administration cleared Repatha for people with hard-to-treat levels of bad cholesterol, according to a statement from the agency.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE